Miami Herald Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Incyte Genomics, Inc. (NQ: INCY)
21.41 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:00 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) 21.02 (1100)
Ask (Size) 21.74 (1100)
Prev. Close 21.41
Today's Range 21.41 - 21.41
52wk Range 15.43 - 26.30
Shares Outstanding 135,749,206
Dividend Yield N/A
Top News
More News
UPDATE: Oppenheimer Reiterates Overweight on Incyte as Jakafi Profile Continues to Improve
June 17, 2013
In a report published on Monday, Oppenheimer analyst Boris Peaker reiterated an Overweight rating on Incyte (NASDAQ: INCY ) and maintained a $25 price target on the company. In the report, Oppenheimer... Read More
category Reiteration , Oppenheimer , Boris Peaker , and 4 more.
from Latest Articles from Benzinga.com
Piper Jaffray Reiterates Overweight Rating on Incyte Following 3-Year Survival Data Presentation
June 17, 2013
In a report published Monday, Piper Jaffray analyst M. Ian Somaiya reiterated an Overweight rating and $27.00 price target on Incyte (NASDAQ: INCY ). In the report, Piper Jaffray noted, “We reiterate... Read More
category Reiteration , Benzinga , INCY , and 4 more.
from Latest Articles from Benzinga.com

More News
Read More
Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
June 16, 2013
from Business Wire News Releases
Incyte Corporation Stock Sees Short Interest Drop 16.2%
June 13, 2013
category Stocks
from Market News Video
Incyte Crosses Above its 10-day MA (INCY)
June 13, 2013
from Comtex SmarTrend® News Briefs
Lilly says arthritis pill effective in mid-stage study
June 13, 2013
category companyNews
from Reuters: Company News
Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis
June 13, 2013
category Contracts , Management , Benzinga , and 5 more.
from Latest Articles from Benzinga.com
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
June 13, 2013
from PR Newswire
Incyte Says FDA Updates Prescribing Info for Jakafi
June 12, 2013
category Benzinga , INCY , News , and 1 more.
from Latest Articles from Benzinga.com
Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information
June 12, 2013
from Business Wire News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here